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Abstract
Background: The use of lengthy, detailed, and complex informed consent forms (ICFs) is of paramount concern in
biomedical research as it may not truly promote the rights and interests of research participants. The extent of
information in ICFs has been the subject of debates for decades; however, no clear guidance is given. Thus, the
objective of this study was to determine the perspectives of research participants about the type and extent of
information they need when they are invited to participate in biomedical research.
Methods: This multi-center, cross-sectional, descriptive survey was conducted at 54 study sites in seven Asia-
Pacific countries. A modified Likert-scale questionnaire was used to determine the importance of each element in
the ICF among research participants of a biomedical study, with an anchored rating scale from 1 (not important)
to 5 (very important).
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Results: Of the 2484 questionnaires distributed, 2113 (85.1%) were returned. The majority of respondents
considered most elements required in the ICF to be ‘moderately important’ to ‘very important’ for their decision
making (mean score, ranging from 3.58 to 4.47). Major foreseeable risk, direct benefit, and common adverse
effects of the intervention were considered to be of most concerned elements in the ICF (mean score = 4.47, 4.
47, and 4.45, respectively).
Conclusions: Research participants would like to be informed of the ICF elements required by ethical guidelines
and regulations; however, the importance of each element varied, e.g., risk and benefit associated with research
participants were considered to be more important than the general nature or technical details of research. Using
a participant-oriented approach by providing more details of the participant-interested elements while avoiding
unnecessarily lengthy details of other less important elements would enhance the quality of the ICF.
Keywords: Consent forms, Informed consent, Disclosure, Information, Ethics, Research subjects
Background
An informed consent form (ICF) is mandatory and
essential in most studies involving human subjects as it
is a primary vehicle for disclosure of information and
documentation of consent [1, 2]. An observation of the
current research practice reveals that ICFs continue to
increase in length and complexity in an attempt to
comply with regulatory requirements [3–6], which
increasingly require more and more elements to address
past and present unethical practice [7, 8]. Lengthy and
complex ICFs decrease the ability of potential partici-
pants to comprehend the ICF content and exercise their
autonomy in decision making to participate in a study
[9]. ICFs have been gradually turned into legal docu-
ments for the protection of researchers and sponsors
rather than documents with relevant information for
decision making of research participants [10].
In an attempt to make ICFs comprehensible, the extent
of information disclosure has been the subject of debates
[11–13]. Lengthy ICFs with full disclosure of everything
may obscure the important and relevant information for
decision making whether to participate in a study [14].
Exhaustive disclosure of detailed information of every sin-
gle aspect related to the study may overwhelm potential
research participants with too excessive information [15].
Based on a systematic review on the desired information
by potential participants of biomedical research, there is
limited empirical evidence on this subject [16]. Generally,
the type and extent of information considered as adequate
and relevant for a person to make a decision are subjective
and difficult to define. In addition, some information
perceived as relevant and important by some research
participants, with respect to their cultural context, may be
absent in even a lengthy ICF as it is not required by ap-
plicable laws and regulations [13]. To address these issues,
empirical data related to the content and extent of infor-
mation that research participants require for their decision
making are needed. The objective of this study was to
determine the perspectives of research participants about
the information they need for their decision making when
they are invited to participate in biomedical research.
Methods
Study design and settings
This multi-center, cross-sectional, descriptive survey was
conducted by the Forum for Ethical Review Committees
in the Asian and Western Pacific region (FERCAP)
Multi-Country Research Team in 7 FERCAP-member
countries, i.e., India, Indonesia, Malaysia, Philippines, Sri
Lanka, Taiwan, and Thailand. The duration of this study
was three months, from June 1 to August 31, 2017, with
a two-week extension in some countries where a sample
size was not met within the three-month period.
Study material
An anonymous, paper-based, structured and self-adminis-
tered questionnaire was developed and reviewed by a
group of FERCAP professionals with expertise in research
surveys, biomedical research, research ethics, and in-
formed consent. Survey items were developed based on
the essential elements required by three major ethical
guidelines and regulations, i.e., Declaration of Helsinki [1],
the International Conference on Harmonization (ICH) for
Good Clinical Practice (GCP) [2], and US Code of Federal
Regulations [17]. A content validity test was conducted to
establish that individual items were relevant to the con-
struct being measured and that key items had not been
omitted in the questionnaire [18]. The questionnaire asked
participants to indicate how important each item was by
giving a rating from 1 to 5 using a modified Likert scale
[19]: 1 = not important, 2 = slightly important, 3 =moder-
ately important, 4 = fairly important, and 5 = very
important. There were open-ended questions in the
questionnaire where the participants could suggest any
additional elements or information that they would like to
receive. Demographic data (age, sex, educational level,
nationality, and occupation) and the participants’ prefer-
ence in page length were included in the questionnaire.
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The think-aloud technique was used to assess how respon-
dents interpreted each item and response anchor [20]. The
questionnaire was then finalized and translated into the
local language for use in each participating country. The
questionnaires in local languages were back-translated into
English by independent individuals who are fluent in both
local and English languages and checked against the
original questionnaire. The translated questionnaire was
piloted in a small group of individuals who were members
of the target population within each respective country.
Study population and sample size determination
This study enrolled individuals who were participating
in ongoing biomedical research – a research study relat-
ing to biology and medicine for healthcare purposes – at
various participating centers (clinical research units or
comparable settings) in 7 countries. Individuals who re-
fused to answer the questionnaire for any reason or had
communication difficulties due to language problems or
cognitive disabilities were excluded.
The sample size for this study was meant to yield a
representative sample under the assumption that the
quantity of interest is measured by a Likert scale.
Following the formula described in Park & Jung (2009)
[21], a sample size of at least 231 would be adequate
when a 5-point scale was used for each Likert-item (k = 5),
with a coefficient of variation of a population (C) = 0.5, a
relative tolerable error (D) = 5%, and a pairwise correlation
coefficient (ρ) = 0.5. The present study was initially
planned to enrol, at least, 300 participants in each country
based on an approximate estimate of 20% of missing data
due to some participants who might skip certain questions
or items that they were not comfortable with.
Study procedure and data collection
Data were collected through an anonymous, self-admin-
istered, structured, paper-based questionnaire. No writ-
ten consent was required for this survey study as an
individual participant’s voluntary completion of the
questionnaire was presumed as consent. Site investiga-
tors collaborated with research staff at clinical research
units or comparable settings and informed research
participants in biomedical research about this ICF study.
Instructions were provided by research staff to potential
participants that they could refuse to answer the ques-
tionnaire for any reason; they could skip any question
that they were unwilling to answer; and they would not
be treated differently because of the responses they gave
in the questionnaire. When participants agreed to take
part in this survey, research staff gave them the ques-
tionnaire. The participants could complete the question-
naire at any time and returned it to the collection box
located at participating centers.
Ethical considerations
The study was conducted in compliance with the
Declaration of Helsinki 2013. The study protocol and
related documents obtained ethical approval from local
ethics committees prior to the commencement of the
survey in each center. This study was considered ‘mini-
mal-risk’ research since it involved only the use of a
questionnaire with no sensitive questions. The informa-
tion was recorded in an anonymous manner. The partic-
ipants could skip any question that they did not want to
answer. Answering the questionnaire and returning it to
the collection box implied the participants’ voluntary
consent for the investigators to use their answers to
meet the research objective. No separate written consent
was required to ensure the participants’ anonymity.
Statistical analysis
Data from 7 countries were gathered, analyzed, and pre-
sented as frequency and percentage, mean and standard
deviation (SD), or median and interquartile range (IQR),
as appropriate. For the participants’ preference in page
length, ‘no limit’ or more than 30 pages was transformed
to the value of 30 for analysis. Likert scale responses of
each item were analyzed using parametric approaches
[22–24]. Differences of variables among countries were
done using the one-way analysis of variance (ANOVA),
followed by Tukey post hoc test. The association
between independent variables (i.e., sex, age, education,
occupation, and type of research involved) and the mean
score of each item was assessed using multivariable
regression analysis. Statistical analyses were performed
using SPSS (IBM Corp. Release 2013. IBM SPSS Statistics
for Windows, Version 22.0. Armonk, NY: IBM Corp). A
p value of less than 0.05 was considered to indicate
statistical significance.
Results
This FERCAP Multi-Country ICF study recruited re-
search participants from 54 study sites in 7 countries. Of
the 2484 questionnaires distributed, 2113 (85.1%) were
returned (Table 1). Demographic data of the respondents
are shown in Table 2. The majority of the respondents
were female (57.9%), middle-aged adults (aged 43.3 ±
16.2 years, range 15–90 years), had a high-school level
of education or lower (64.5%).
Overall, the respondents wanted to know most ele-
ments of the ICF content required (Table 3), with mean
scores ranging from 3.58 (about wanting to know the
number of participants) to 4.47 (for major foreseeable
risk) as shown in Fig. 1. All of the 37 items were rated
as ‘moderately important’ or higher among approxi-
mately 80% of the respondents to as high as 97.4% of
them highly interested in the direct benefit of research
(see Additional file 1: Table S1). None of the items were
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considered ‘slightly important’ or lower in more than
one-third of the respondents from any country. Statisti-
cally significant differences were found among countries
in the mean score of all the 37 items when one-way
ANOVA was applied (p < 0.001) (data not shown).
Major foreseeable risk, direct benefit, and common ad-
verse effects of the intervention were considered to be of
most concern among the respondents (with mean scores
of 4.47, 4.47, and 4.45, respectively) as shown in Fig. 1.
In contrast, items about payment and/or remuneration,
conflict of interest, the source of funds and sponsors,
and the number of participants involved were considered
to be of relatively less concern (with mean scores of
3.85, 3.79, 3.75, and 3.58, respectively). Nevertheless,
there was slight variation in the items that were of most
and of least concern among research participants in dif-
ferent countries (Table 4).
Demographic characteristics were found to be associ-
ated with the scores in several items. Higher scores in the
desire to receive detailed information were associated with
female gender (in 34 out of the 37 items), healthcare pro-
fession (in 24 out of the 37 items), younger age (in 11 out
of the 37 items), and higher educational levels (in 10 out
of the 37 items) (see Additional file 2: Table S2). Those
participating in experimental research wanted more infor-
mation in 30 out of the 37 items, as compared to those
participating in observational research.
The maximum, acceptable number of pages in the ICF
that research participants preferred to read was 6.3 ± 6.1
pages (median, 5 pages; IQR, 2–8 pages). However, this
value varied among countries. The Taiwanese respondents
reported the longest maximum, acceptable number of
pages that they would read (12.3 ± 10.8 pages, n = 174),
followed by the Filipino (7.7 ± 6.5 pages, n = 200), Ma-
laysian (7.0 ± 5.7 pages, n = 438), Thai (5.3 ± 3.1 pages,
n = 22), Indian (5.0 ± 3.2 pages, n = 378), Indonesian
(4.1 ± 3.3 pages, n = 242), and Sri Lankan respondents
(3.7 ± 3.3 pages, n = 213) (see Additional file 3: Table S3).
Multivariable analysis identified factors that were asso-
ciated with the maximum, acceptable number of pages
in the ICF, i.e., occupation (healthcare profession vs.
non-healthcare profession, p < 0.001) and type of research
involved (experimental vs. observational, p < 0.001). When
compared to their counterparts, research participants in
the healthcare profession and those participating in the
experimental research were more agreeable to reading
longer ICFs (8.6 vs. 5.9 pages, p < 0.001; 6.8 vs. 5.5 pages,
p < 0.001, respectively) (see Additional file 4: Figure S1).
There were 58 comments from 56 respondents, suggest-
ing additional information needs. The majority of these
comments showed their desire to know about whether to
be informed of research results (n = 37) and the location
where the research will be conducted (n = 8). A few
respondents mentioned that they wanted to receive infor-
mation about legal liability related to research (n = 4),
other study sites involved (n = 2), clinical phase of the trial
Table 1 Number of questionnaires distributed and collected by each country
Country Site (n) Questionnaires distributed (n) Questionnaires collected (n)
India 4 434 410 (94.5%)
Indonesia 1 362 299 (82.6%)
Malaysia 28 508 508 (100.0%)
Philippines 12 508 267 (52.6%)
Sri Lanka 6 335 303 (90.4%)
Taiwan 1 229 229 (100.0%)
Thailand 2 108 97 (89.8%)
54 2484 2113 (85.1%)
Table 2 Demographic data of the respondents





15–30 years 638 (30.4%)
31–45 years 546 (26.0%)
46–60 years 514 (24.5%)
61–90 years 401 (19.1%)
Educational level
High school or lower 1331 (64.5%)
Bachelor/diploma degree 525 (25.4%)
Master/doctor degree 208 (10.1%)
Occupation
Healthcare profession 245 (12.4%)
Non-healthcare profession† 1730 (87.6%)
Type of research involved
Experimental research 1234 (59.8%)
Observational research 830 (40.2%)
†Non-healthcare profession, including students, housewives, retirees, and
the unemployed
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Table 3 The element and extent of information that research participants wanted to receive
Element Abbreviation n Extent of information
Mean SE SD Median IQR
1. General items
1.1 Title of research Title (n = 2100) 4.33 0.021 0.941 5 (4–5)
1.2 Name of researchers Name (n = 2091) 4.08 0.024 1.088 4 (4–5)
1.3 Affiliation or organization of researchers Affil (n = 2083) 4.10 0.023 1.035 4 (4–5)
1.4 Recognition that this is research Resea (n = 2095) 4.29 0.021 0.963 5 (4–5)
1.5 Contact information regarding the research study cInfo (n = 2040) 4.29 0.020 0.899 5 (4–5)
1.6 Contact information about the participant’s right cInfoR (n = 2035) 4.26 0.021 0.932 5 (4–5)
1.7 Source of funds and sponsors Spons (n = 2082) 3.75 0.027 1.233 4 (3–5)
1.8 Conflict of interest Coi (n = 2020) 3.79 0.027 1.228 4 (3–5)
2. Study-specific items
2.1 Background and rationale of research Backg (n = 2084) 4.16 0.021 0.966 4 (4–5)
2.2 Purpose of research Purp (n = 2093) 4.35 0.019 0.868 5 (4–5)
2.3 Eligibility of the participant Eligib (n = 2104) 4.28 0.020 0.915 5 (4–5)
2.4 Study design of research Desig (n = 2078) 3.96 0.023 1.071 4 (3–5)
2.5 Interventions under investigation Interv (n = 2080) 4.37 0.020 0.895 5 (4–5)
2.6 Common adverse effects of the intervention coAE (n = 2082) 4.45 0.019 0.857 5 (4–5)
2.7 All possible adverse effects of the intervention allAE (n = 2086) 4.36 0.020 0.933 5 (4–5)
2.8 Other options or alternative treatments Altern (n = 2088) 4.02 0.024 1.093 4 (3–5)
2.9 Duration of the participant’s participation Durat (n = 2069) 4.17 0.021 0.971 4 (4–5)
2.10 Schedule and procedure Proc (n = 2089) 4.29 0.020 0.894 5 (4–5)
2.11 Identification of any experimental procedures eProc (n = 2075) 4.11 0.022 1.013 4 (4–5)
2.12 Number of participants involved Numb (n = 2092) 3.58 0.027 1.218 4 (3–5)
2.13 Criteria for termination Term (n = 2045) 4.23 0.022 0.975 4 (4–5)
3. Items related to the subject’s right
3.1 Voluntary participation Volun (n = 2093) 4.19 0.022 1.014 4 (4–5)
3.2 Consequence of withdrawal cWith (n = 2039) 4.04 0.024 1.097 4 (4–5)
3.3 Right to receive new information nInfo (n = 2048) 4.25 0.020 0.927 4 (4–5)
4. Items related to risk-benefit
4.1 Major foreseeable risk mjRis (n = 2077) 4.47 0.020 0.902 5 (4–5)
4.2 Minor foreseeable risk miRis (n = 2077) 4.25 0.021 0.968 5 (4–5)
4.3 Possibly unforeseeable risk ufRis (n = 2043) 4.27 0.024 1.064 5 (4–5)
4.4 Direct health benefit dBene (n = 2088) 4.47 0.017 0.793 5 (4–5)
4.5 Indirect benefit iBene (n = 2096) 4.31 0.019 0.865 5 (4–5)
4.6 Societal benefit sBene (n = 2049) 4.30 0.020 0.901 5 (4–5)
4.7 Post-trial benefit or provision pBene (n = 2048) 4.23 0.021 0.950 4 (4–5)
5. Items related to data and sample storage
5.1 Confidentiality and the limit of confidentiality Confi (n = 2048) 4.29 0.022 0.984 5 (4–5)
5.2 Storage of human material Stora (n = 2041) 3.97 0.025 1.148 4 (3–5)
5.3 Reuse of human material Reuse (n = 2043) 4.04 0.025 1.113 4 (4–5)
6. Items related to monetary issues
6.1 Payment and/or remuneration Paym (n = 2040) 3.85 0.026 1.156 4 (3–5)
6.2 Anticipated expense Expen (n = 2025) 4.00 0.024 1.099 4 (4–5)
6.3 Compensation for injury Compe (n = 2038) 4.32 0.020 0.912 5 (4–5)
IQR interquartile range, SD standard deviation, SE standard error of the mean
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(n = 2), status of the trial, testimony, and approval (n = 2),
research budget (n = 2), and related sources of infor-
mation (n = 1).
Discussion
This FERCAP Multi-Country ICF study is the largest
empirical study on this subject, involving 2113 actual
research participants from 54 study sites in 7 countries.
It attempted to determine the information that research
participants considered to be of importance for their
decision making whether to participate in biomedical
research. The results indicate that the ICF elements
required by ethical guidelines and regulations concur
with the information the majority of research partici-
pants in 7 Asia-Pacific countries want to know.
The top three items which were of most concern to the
respondents in this study were related to the concepts of
risks and benefits (i.e., major foreseeable risk, direct bene-
fit, and common adverse effects of the intervention). This
finding is consistent with previous numerous studies
indicating that research participants regard the risk and
benefit associated with their participation to be more
important than the general nature or technical details of
research [25–27]. Thus, such information should be made
a salient feature of an ICF when enrolling potential partic-
ipants. While the written ICF provided in biomedical
research should contain the necessary elements, it should
be properly edited and streamlined to ensure concise
information to reflect the results of this study. A
participant-oriented approach that considers the import-
ance of each element and emphasis on items perceived as
more important than others could adequately address
participant needs and avoid unnecessarily lengthy details
that are of no interest to them [13]. Information should be
provided to the extent that it does not detract from what
participants want to know and what is needed for a valid
consent (i.e., sufficient information, comprehension, and
voluntariness) [28]. Information relating to the concepts
of risks and benefits, for example, should be described
extensively and made salient to potential research partici-
pants, while the general nature or technical details of
research can be described briefly.
Disclosure requirements based on the elements required
in the three major ethical guidelines and regulations – the
Declaration of Helsinki [1], ICH GCP [2], and US federal
regulations [17] – are generally sufficient to cover all the
aspects that most research participants would like to
know. However, this study identified additional informa-
tion that some participants want to be informed about.
Information regarding the disclosure of individual results
to participants at the end of the study is one of the ele-
ments that a sizable number of participants would like to
know. This finding is in line with a recent systematic
review reporting that several participants wanted to be
told about dissemination of study results [16]. This issue
has lately been addressed in the revised US Federal Policy
for the Protection of Human Subjects, promulgated in
January 2017, that requires “a statement regarding whether
clinically relevant research results, including individual
research results, will be disclosed to subjects, and if so,
under what conditions” [7]. Nevertheless, it is important
to note that disclosure of individual research results (IRRs)
might pose psychosocial risks to research participants and
their relatives in some settings, especially in genetic-associ-
ation research [29]. Hence, conditions for disclosure of
IRRs should be predefined, e.g., the results that will be
conveyed to the participants should be analytically valid,
medically important, and actionable, with respect to the
participants’ preference [30–32]. In addition, a few respon-
dents raised concerns about legal liability related to
research while another wanted to know other study sites
involved. When individuals would like to obtain certain
additional information that may be relevant to their
concerns, investigators may be required to disclose or pro-
vide them on a case-by-case basis [28].
The analysis of the respondents’ acceptable page
length suggests that an approximately 6-page-long ICF
seems to be acceptable to general populations in 7
Fig. 1 The element and extent of information that research participants wanted to receive
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countries across the Asia-Pacific region. This result is in
line with other evidence promoting the use of short and
concise ICFs in biomedical research [33]. As shown in a
previous empirical study on the preferred length of ICFs,
most participants preferred concise, rather than detailed
information when they made a decision on trial partici-
pation [11]. Another evidence also suggested that a con-
cise ICF is as valid as a detailed, standard ICF to comply
with ethical requirements [34]. Although concise forms
may not be able to improve participants’ satisfaction
with the consent process in all settings, they still have
other advantages to the readers as ones are less likely to
thoroughly read long forms and wholly absorb extensive
information [35]. Recently, there has been a major
change in the ethical guidelines and regulations that
encourages investigators and sponsors to summarize
relevant and important information in a few pages [7, 8].
An ICF used in biomedical research should no longer be
an unduly long document, with key information often
being hard to find [33]. Concise ICFs with complete
information as required by regulations can be developed,
for example, using the SIDCER ICF methodology, which
has recently been validated and published [36–39]. This
methodology requires a thorough understanding of the
Table 4 Ranks of the elements considered to be of most concern by research participants from each country
The values that are more than ‘mean + 1 SD’ (considered to be of most concern) is in RED columns; those within ‘mean ± 1 SD’ is in YELLOW columns; and those
less than ‘mean – 1 SD’ (considered to be of least concern) is in GREEN columns
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protocol followed by the summarized information rele-
vant to the interest and concerns of research participants
[36]. Visual aids such as summary tables, highlighting
keywords and pictographs should be used, when appro-
priate, to simplify and help participants understand
detailed and complex information [36, 40]. Nevertheless,
some groups of participants, such as the Taiwanese,
might indicate a preference for a relatively longer ICF
which contains more detailed and comprehensive infor-
mation. Supplementary provision of detailed information
could be offered to such groups in additional papers
(e.g., appendices) or via websites [25, 33].
A closer examination revealed that female participants,
healthcare professionals, younger age groups, and those
with high educational levels wanted to receive more
information about several items when compared to their
counterparts. This indicates the different needs of different
groups for relevant biomedical or clinical trial information
[41]. Furthermore, research participants from different
countries showed slight variation in their interests in each
element. This is in line with other studies which suggested
that information needs may somewhat vary across diverse
socioeconomic backgrounds and cultural settings [42–44].
However, there is also a possibility that the difference of
variables among countries might not be a genuine differ-
ence in ethical views; rather, it might be influenced by re-
sponse styles across countries or cultural backgrounds [45].
The results of this extensive multi-country survey, in-
volving over 2000 actual research participants at 54 study
sites across 7 Asia-Pacific countries, may be considered to
be representative of the perspectives of general popula-
tions in the Asia-Pacific region. However, this study has a
limitation as it lacks data on the perspectives of those
asked to provide surrogate consent for others (e.g., parents
or other legally acceptable representatives). It is reasonable
to assume that the content and extent of information
needed among surrogates may be different from what we
observed among actual research participants in this study
[46, 47]. In addition, different levels of research risk (e.g.,
low-risk studies with little or no intervention versus
high-risk studies with invasive interventions) may result in
different needs for trial information among research
participants [25, 40]. Further research is required to help
tailor ICFs toward more specific types of biomedical
research, including biobank research, and population
subgroups, such as the study previously done by Casarett
et al. for pain research [48].
Conclusions
In summary, what research participants would like to be
informed of mostly concurred with the elements of the
ICF content required by the current ethical guidelines
and regulations. However, some elements may be more
important than others and such information should be
made salient to research participants. The study results
provide important insights to better address the chal-
lenges of determining the extent of information in ICFs
that is considered to be important and adequate from
research participants’ perspectives.
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